Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020

Reuters2026/08/14 10:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lakewood-Amedex posted a net loss of $3.77 million for the quarter ended June 30, 2026, widening from the prior-year period.
Operating loss widened to $3.79 million as total operating expenses climbed to $3.79 million.
Research and development spending more than doubled to $503,020, driven by higher manufacturing, regulatory and clinical planning for Nu-3 Phase 2a.
General and administrative costs jumped to $3.29 million, mainly due to $2.4 million in noncash professional services tied to stock issuance.
Series C Convertible Preferred Stock private placement raised about $6.8 million net; common stock began trading on Nasdaq Capital Market on April 23.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089380), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020

You may also like

Crypto prices